Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09TPF
|
||||
| Former ID |
DAP000979
|
||||
| Drug Name |
Molindone
|
||||
| Synonyms |
Moban; Molindona; Molindonum; Molindone Monohydrochloride; Moban (TN); Molindona [INN-Spanish]; Molindone (INN); Molindone (MOL); Molindone [INN:BAN]; Molindonum [INN-Latin]; (+-)-Molindone; 3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one; 3-Ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5H)-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydro-4H-indol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-4,5,6,7-tetrahydro-1H-indol-4-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Approved | [1], [2] | ||
| Therapeutic Class |
Antipsychotic Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H24N2O2
|
||||
| InChI |
InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3
|
||||
| InChIKey |
KLPWJLBORRMFGK-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 7416-34-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9439, 7784248, 8167438, 10534390, 11467063, 11468183, 11486836, 14799490, 26755691, 29291008, 46504744, 47320783, 47320784, 48289519, 48289520, 48365147, 48416291, 49699386, 49984921, 50111112, 50836898, 57331496, 85209915, 85787545, 90341242, 92723324, 96024914, 99375691, 103167157, 104021724, 104179135, 104359414, 117423090, 117597268, 125562976, 126626997, 126652518, 126663373, 128400085, 131377755, 134223702, 134338250, 134987862, 135650621, 135874693, 137260961, 140261912, 143493298, 152038486, 152235779
|
||||
| SuperDrug ATC ID |
N05AE02
|
||||
| SuperDrug CAS ID |
cas=007416344
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Binder | [3], [4] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 017111. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 207). | ||||
| REF 3 | Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002083. | ||||
| REF 4 | Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998 Mar;3(2):123-34. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.